Statins and the vascular endothelial inflammatory response

Trends in Immunology

Volumn 28, Issue 2, 2007, Pages 88-98

  Greenwood, John ^a   Mason, Justin C ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHEMOKINE; CHEMOKINE RECEPTOR; COMPACTIN; FLUINDOSTATIN; GUANOSINE TRIPHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEVINOLIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; FIBRINOLYSIS; GENE EXPRESSION; HUMAN; INFLAMMATION; LEUKOCYTE; NONHUMAN; PATHOGENESIS; REVIEW; VASCULAR ENDOTHELIUM;

ANIMALS; CELL ADHESION; ENDOTHELIAL CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; NITRIC OXIDE; SIGNAL TRANSDUCTION;

EID: 33846639179     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2006.12.003     Document Type: Review

References (90)

1. Greenwood J., et al. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat. Rev. Immunol. 6 (2006) 358-370
2. Jury E.C., and Ehrenstein M.R. Statins: immunomodulators for autoimmune rheumatic disease?. Lupus 14 (2005) 192-196
3. Ehrenstein M.R., et al. Statins for atherosclerosis - as good as it gets?. New Engl. J. Med. 352 (2005) 73-75
4. Weitz-Schmidt G., et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7 (2001) 687-692
5. Liao J.K., and Laufs U. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 89-118
6. Kinlay S. Potential vascular benefits of statins. Am. J. Med. 118 Suppl. 12A (2005) 62-67
7. Beckman J.A., and Creager M.A. The nonlipid effects of statins on endothelial function. Trends Cardiovasc. Med. 16 (2006) 156-162
8. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
9. Wolfrum S., et al. Endothelium-dependent effects of statins. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 729-736
10. Jain M.K., and Ridker P.M. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat. Rev. Drug Discov. 4 (2005) 977-987
11. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. New Engl. J. Med. 352 (2005) 1685-1695
12. Mason J.C. Statins and their role in vascular protection. Clin. Sci. (Lond.) 105 (2003) 251-266
13. McCarey D.W., et al. Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?. Arthritis Res. Ther. 7 (2005) 55-61
14. Van Doornum S., et al. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann. Rheum. Dis. 63 (2004) 1571-1575
15. Hermann F., et al. Simvastatin improves endothelial function in patients with rheumatoid arthritis. J. Am. Coll. Cardiol. 45 (2005) 461-464
16. Kwak B., et al. Statins as a newly recognised type of immunomodulator. Nat. Med. 6 (2000) 1399-1402
17. Sadeghi M.M., et al. Inhibition of interferon-γ-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation 71 (2001) 1262-1268
18. Muczynski K.A., et al. Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: characterization, isolation, and regulation of MHC class II expression. J. Am. Soc. Nephrol. 14 (2003) 1336-1348
19. Geissler I., et al. In vivo suppression of major histocompatibility complex class II expression on porcine vascular endothelial cells by an HMG-CoA reductase inhibitor. Transplantation 81 (2006) 922-926
20. Kuipers H.F., and van den Elsen P.J. Statins and control of MHC2TA gene transcription. Nat. Med. 11 (2005) 365-366
21. Wagner A.H., et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 1784-1789
22. Lin R., et al. Lovastatin reduces apoptosis and downregulates the CD40 expression induced by TNF-α in cerebral vascular endothelial cells. Curr. Neurovasc. Res. 3 (2006) 41-47
23. Schonbeck U., et al. Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation 106 (2002) 2888-2893
24. Mulhaupt F., et al. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc. Res. 59 (2003) 755-766
25. Romano M., et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab. Invest. 80 (2000) 1095-1100
26. Zineh I., et al. Modulatory effects of atorvastatin on endothelial cell-derived chemokines, cytokines, and angiogenic factors. Pharmacotherapy 26 (2006) 333-340
27. Veillard N.R., et al. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis 188 (2006) 51-58
28. Pruefer D., et al. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 2894-2900
29. Stalker T.J., et al. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br. J. Pharmacol. 133 (2001) 406-412
30. Li D., et al. Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1. J. Pharmacol. Exp. Ther. 302 (2002) 601-605
31. Omi H., et al. Statins inhibit high glucose-mediated neutrophil-endothelial cell adhesion through decreasing surface expression of endothelial adhesion molecules by stimulating production of endothelial nitric oxide. Microvasc. Res. 65 (2003) 118-124
32. Sadeghi M.M., et al. Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein. J. Immunol. 165 (2000) 2712-2718
33. Rasmussen L.M., et al. Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells. Biochem. J. 360 (2001) 363-370
34. Schmidt A., et al. Lovastatin-stimulated superinduction of E-selectin, ICAM-1 and VCAM-1 in TNF-α activated human vascular endothelial cells. Atherosclerosis 164 (2002) 57-64
35. Bernot D., et al. Effect of atorvastatin on adhesive phenotype of human endothelial cells activated by tumor necrosis factor α. J. Cardiovasc. Pharmacol. 41 (2003) 316-324
36. Dimitrova Y., et al. Effects of statins on adhesion molecule expression in endothelial cells. J. Thromb. Haemost. 1 (2003) 2290-2299
37. Dunoyer-Geindre S., et al. Fluvastatin increases the expression of adhesion molecules, monocyte chemoattractant protein-1 and tissue factor in HUVEC stimulated by patient IgG fractions containing antiphospholipid antibodies. Thromb. Haemost. 93 (2005) 339-345
38. Nubel T., et al. Lovastatin inhibits Rho-regulated expression of E-selectin by TNFα and attenuates tumor cell adhesion. FASEB J. 18 (2004) 140-142
39. Prasad R., et al. Inhibition of phosphoinositide 3 kinase-Akt (protein kinase B)-nuclear factor-kappa B pathway by lovastatin limits endothelial-monocyte cell interaction. J. Neurochem. 94 (2005) 204-214
40. Takeuchi S., et al. Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC. Biochem. Biophys. Res. Commun. 269 (2000) 97-102
41. Chung H.K., et al. Statin inhibits interferon-γ-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells. Exp. Mol. Med. 34 (2002) 451-461
42. Okouchi M., et al. Cerivastatin ameliorates high insulin-enhanced neutrophil-endothelial cell adhesion and endothelial intercellular adhesion molecule-1 expression by inhibiting mitogen-activated protein kinase activation. J. Diabetes Complications 17 (2003) 380-386
43. Rezaie-Majd A., et al. Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 397-403
44. Zapolska-Downar D., et al. Simvastatin modulates TNFα-induced adhesion molecules expression in human endothelial cells. Life Sci. 75 (2004) 1287-1302
45. Xenos E.S., et al. Nitric oxide mediates the effect of fluvastatin on intercellular adhesion molecule-1 and platelet endothelial cell adhesion molecule-1 expression on human endothelial cells. Ann. Vasc. Surg. 19 (2005) 386-392
46. Landsberger M., et al. Cerivastatin reduces cytokine-induced surface expression of ICAM-1 via increased shedding in human endothelial cells. Atherosclerosis 190 (2007) 43-52
47. Katoh M., et al. Fluvastatin inhibits O2- and ICAM-1 levels in a rat model with aortic remodeling induced by pressure overload. Am. J. Physiol. Heart Circ. Physiol. 281 (2001) H655-H660
48. Li W., et al. Rosuvastatin attenuates monocyte-endothelial cell interactions and vascular free radical production in hypercholesterolemic mice. J. Pharmacol. Exp. Ther. 313 (2005) 557-562
49. Wei H., et al. Statin-inhibited endothelial permeability could be associated with its effect on PECAM-1 in endothelial cells. FEBS Lett. 579 (2005) 1272-1278
50. Greenwood J., et al. Lymphocyte migration into the central nervous system: implication of ICAM-1 signalling at the blood-brain barrier. Vascul. Pharmacol. 38 (2002) 315-322
51. Barreiro O., et al. Dynamic interaction of VCAM-1 and ICAM-1 with moesin and ezrin in a novel endothelial docking structure for adherent leukocytes. J. Cell Biol. 157 (2002) 1233-1245
52. Carman C.V., and Springer T.A. A transmigratory cup in leukocyte diapedesis both through individual vascular endothelial cells and between them. J. Cell Biol. 167 (2004) 377-388
53. Greenwood J., et al. Lovastatin inhibits brain endothelial Rho-dependent lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J. 17 (2003) 905-907
54. Gegg M.E., et al. Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction. J. Immunol. 174 (2005) 2327-2335
55. Cook-Mills J.M., et al. Calcium mobilization and Rac1 activation are required for VCAM-1 (vascular cell adhesion molecule-1) stimulation of NADPH oxidase activity. Biochem. J. 378 (2004) 539-547
56. van Wetering S., et al. Reactive oxygen species mediate Rac-induced loss of cell-cell adhesion in primary human endothelial cells. J. Cell Sci. 115 (2002) 1837-1846
57. van Wetering S., et al. VCAM-1-mediated Rac signaling controls endothelial cell-cell contacts and leukocyte transmigration. Am. J. Physiol. Cell Physiol. 285 (2003) C343-C352
58. Wagner A.H., et al. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 61-69
59. Meroni P.L., et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-β2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum. 44 (2001) 2870-2878
60. Dichtl W., et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 58-63
61. Holschermann H., et al. Statins prevent NF-κB transactivation independently of the IKK-pathway in human endothelial cells. Atherosclerosis 185 (2006) 240-245
62. Suzuki T., et al. Vascular implications of the Kruppel-like family of transcription factors. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1135-1141
63. Parmar K.M., et al. Statins exert endothelial atheroprotective effects via the KLF2 transcription factor. J. Biol. Chem. 280 (2005) 26714-26719
64. Sen-Banerjee S., et al. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation 112 (2005) 720-726
65. van Thienen J.V., et al. Shear stress sustains atheroprotective endothelial KLF2 expression more potently than statins through mRNA stabilization. Cardiovasc. Res. 72 (2006) 231-240
66. Inoue I., et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of mRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPARα) in primary endothelial cells. Life Sci. 67 (2000) 863-876
67. Martin G., et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I. J. Clin. Invest. 107 (2001) 1423-1432
68. Paumelle R., et al. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-α via inhibition of the protein kinase C signaling pathway. Circ. Res. 98 (2006) 361-369
69. Laufs U. Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur. J. Clin. Pharmacol. 58 (2003) 719-731
70. Rikitake Y., and Liao J.K. Rho GTPases, statins, and nitric oxide. Circ. Res. 97 (2005) 1232-1235
71. Liao J.K. Isoprenoids as mediators of the biological effects of statins. J. Clin. Invest. 110 (2002) 285-288
72. Ming X.F., et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol. Cell. Biol. 22 (2002) 8467-8477
73. Landsberger M., et al. Blockade of geranylgeranylation by rosuvastatin upregulates eNOS expression in human venous endothelial cells. Biochem. Biophys. Res. Commun. 336 (2005) 1005-1009
74. Kureishi Y., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 6 (2000) 1004-1010
75. Urbich C., et al. Double-edged role of statins in angiogenesis signaling. Circ. Res. 90 (2002) 737-744
76. -/- mice in vivo. Circulation 107 (2003) 2480-2486
77. Furukawa S., et al. Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study. Ann. Rheum. Dis. 65 (2006) 1118-1120
78. Ifergan I., et al. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann. Neurol. 60 (2006) 45-55
79. Stamatovic S.M., et al. Potential role of MCP-1 in endothelial cell tight junction 'opening': signaling via Rho and Rho kinase. J. Cell Sci. 116 (2003) 4615-4628
80. Zeng L., et al. HMG CoA reductase inhibition modulates VEGF-induced endothelial cell hyperpermeability by preventing RhoA activation and myosin regulatory light chain phosphorylation. FASEB J. 19 (2005) 1845-1847
81. Mooradian A.D., et al. Statins ameliorate endothelial barrier permeability changes in the cerebral tissue of streptozotocin-induced diabetic rats. Diabetes 54 (2005) 2977-2982
82. Liao J.K. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am. J. Cardiol. 96 (2005) 24F-33F
83. Wassmann S., et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 300-305
84. Hsu M., et al. Tissue-specific effects of statins on the expression of heme oxygenase-1 in vivo. Biochem. Biophys. Res. Commun. 343 (2006) 738-744
85. Wilson S.H., et al. Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation 105 (2002) 415-418
86. Vecchione C., and Brandes R.P. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ. Res. 91 (2002) 173-179
87. Mason J.C., et al. Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury. Circ. Res. 91 (2002) 696-703
88. Kinderlerer A.R., et al. Statin-induced expression of CD59 on vascular endothelium in hypoxia. A potential mechanism for the anti-inflammatory actions of statins in rheumatoid arthritis. Arthritis Res. Ther. 8 (2006) R130-R141
89. Landmesser U., et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111 (2005) 2356-2363
90. Bellosta S., et al. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109 Suppl. 1 (2004) III-50-III-57